TrialCPT: pharmacometrics & systems pharmacology2016

Bridging Sunitinib Exposure to Time-to-Tumor Progression in Hepatocellular Carcinoma Patients With Mathematical Modeling of an Angiogenic Biomarker.

S Ait-Oudhia et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.